Flentje D, Schlag P
Eur J Surg Oncol. 1985 Sep;11(3):227-33.
Based on the concept of a combined modality cancer treatment in surgical oncology, the use of the human tumour colony assay for routine chemosensitivity testing and prospective treatment planning was investigated in 204 surgical biopsies of primary human solid tumours. The majority of the tumours (135/204) were of gastro-intestinal (GI) origin. Sufficient growth for drug testing occurred in 29-67% of all tumours depending on the tumour type, with a mean of 36% in GI-carcinomas. Chemosensitivity testing in vitro against standard anti-cancer agents correlated well with clinical experience, 5-FU and FUDR being the most active drugs (27% respectively 24% sensitive tumours in vitro) in GI-carcinomas. Relatively good agreement of in vitro/in vivo correlations was seen with an overall of 25/32 correct predictions in GI and other tumours. Predictivity was particularly good for loco-regional chemotherapy. Nevertheless, the limited in vitro growth rate of gastro-intestinal tumour specimens and their chemoresistance restrict the use of this method-in particular with respect to individual treatment planning.
基于外科肿瘤学中联合模式癌症治疗的概念，在204例原发性人类实体瘤手术活检中研究了使用人类肿瘤集落测定法进行常规化疗敏感性测试和前瞻性治疗规划。大多数肿瘤（135/204）起源于胃肠道（GI）。根据肿瘤类型，29%至67%的所有肿瘤出现了足以进行药物测试的生长情况，胃肠道癌的平均生长率为36%。针对标准抗癌药物的体外化疗敏感性测试与临床经验相关性良好，5-氟尿嘧啶（5-FU）和氟尿苷（FUDR）是胃肠道癌中最具活性的药物（体外敏感肿瘤分别为27%和24%）。在胃肠道肿瘤和其他肿瘤中，体外/体内相关性的总体预测正确率为25/32，显示出相对较好的一致性。局部区域化疗的预测性尤其良好。然而，胃肠道肿瘤标本的体外生长速率有限及其化疗耐药性限制了该方法的应用——特别是在个体治疗规划方面。
